Aradigm Corp is a United States-based company. The Company is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. Its inhaled ciprofloxacin formulations are also product candidates for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, and for the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever and inhaled anthrax.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	4.89M 4.29M 3.99M 3.66M 6.88M 470M 6.99M 47.38M 18.51M 231M 18.34M 17.94M 800M	P/E 2016	-0.72x	P/E 2017	-9.3x
Enterprise Value	12.8M 11.24M 10.45M 9.59M 18.02M 1.23B 18.3M 124M 48.5M 606M 48.04M 47.01M 2.1B	EV / Sales 2016	73.3x	EV / Sales 2017	7.27x
Free-Float	60.28%	Yield 2016 *	-	Yield 2017	-

20-06-29	Aradigm Corporation Went Out of Business	CI
20-06-12	Modified Combined Liquidation Plan and Discosure Statement Approved for Aradigm Corporation	CI
20-04-27	Revised Disclosure Statement Conditionally Approved for Aradigm Corporation	CI
20-04-08	Combined Liquidation Plan and Disclosure Statement Filed by Aradigm Corporation	CI
20-03-30	Grifols, S.A. completed the acquisition of Assets and Intellectual Property of Lipoquin, Free Ciprofloxacin, Apulmiq from Aradigm Corporation (OTCPK:ARDM.Q).	CI
20-03-30	Motion for Asset Sale Approved for Aradigm Corporation	CI
20-03-09	Bidding Procedure Approved for Aradigm Corporation	CI
20-02-20	Motion for Asset Sale Filed by Aradigm Corporation	CI
20-02-20	Grifols, S.A. entered into an asset purchase agreement to acquire Assets and Intellectual Property of Lipoquin, Free Ciprofloxacin, Apulmiq from Aradigm Corporation (OTCPK:ARDM.Q) for $6.3 million.	CI
19-11-05	Second Motion for Exclusivity Period Extension Approved For Aradigm Corporation	CI
19-10-30	Aradigm Corporation Announces Withdrawal of European Marketing Authorization Application for Linhaliq	CI
19-10-21	Aradigm Corporation Receives Feedback Following an Oral Explanation with the European Medicines Agency	CI
19-07-19	Motion for Exclusivity Period Extension Approved For Aradigm Corporation	CI

20-06-15	ARADIGM CORP : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
20-06-04	ARADIGM CORP : Other Events (form 8-K)	AQ
20-04-30	ARADIGM CORP : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
20-04-13	ARADIGM CORP : Other Events (form 8-K)	AQ
20-04-06	Aradigm : Announces Sale of Assets to Grifols, S.A.	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARADIGM CORPORATION	+36.88%	+25.50%	-	-	702K
LONZA GROUP AG	+1.07%	-3.49%	-3.35%	+10.44%	46.86B
REVOLUTION MEDICINES, INC.	+0.25%	+1.65%	+399.22%	+634.87%	40.23B
BEONE MEDICINES AG	-0.27%	+4.45%	+11.81%	+65.64%	36.23B
IQVIA HOLDINGS INC.	+0.35%	+0.87%	+4.46%	-10.16%	34.72B
CELLTRION, INC.	+3.14%	+1.02%	+4.76%	+40.92%	27.89B
MEDPACE HOLDINGS, INC.	-0.73%	+11.84%	+34.39%	+134.36%	16.79B
ASCENDIS PHARMA A/S	+0.47%	-2.74%	-	-	16.74B
EUROFINS SCIENTIFIC SE	+0.42%	-5.52%	-3.43%	+9.03%	13.12B
ICON PUBLIC LIMITED COMPANY	-2.68%	-2.49%	-11.36%	-33.61%	12.7B
Average	+3.89%	+0.83%	+54.56%	+106.44%	27.25B
Weighted average by Cap.	+0.48%	+0.91%	+74.42%	+136.27%

	2016	2017
Net sales	195K 171K 159K 146K 275K 18.78M 279K 1.89M 739K 9.23M 732K 716K 31.92M	14.46M 12.7M 11.82M 10.84M 20.37M 1.39B 20.68M 140M 54.81M 685M 54.3M 53.13M 2.37B
Net income	-32.94M -28.93M -26.9M -24.69M -46.39M -3.17B -47.1M -319M -125M -1.56B -124M -121M -5.39B	-10.7M -9.4M -8.74M -8.02M -15.08M -1.03B -15.31M -104M -40.57M -507M -40.19M -39.32M -1.75B
Net Debt	-9.37M -8.23M -7.66M -7.02M -13.2M -903M -13.4M -90.9M -35.51M -444M -35.18M -34.42M -1.53B	7.91M 6.95M 6.46M 5.93M 11.14M 762M 11.32M 76.75M 29.99M 375M 29.71M 29.07M 1.3B

Aradigm Corporation Stock Nasdaq

Stocks

US0385054004

Biotechnology & Medical Research

Valuation: Aradigm Corporation

Latest news : Aradigm Corporation

Press Releases: Aradigm Corporation

Quotes and Performance

Other Biotechnology & Medical Research

Financials

Company Profile